ArriVent BioPharma (AVBP) Proxy Filing summary

Executive summary

• The annual meeting will be held virtually on June 18, 2025, with voting available online, by phone, or mail.

• Stockholders will vote on electing two directors and ratifying the appointment of PricewaterhouseCoopers LLP as the independent auditor for 2025.

• Proxy materials are distributed primarily via the Internet to reduce costs and environmental impact.

• Only stockholders of record as of April 21, 2025, are entitled to vote; 34,045,193 shares are outstanding.

Voting matters and shareholder proposals

• Two directors, Zhengbin (Bing) Yao, Ph.D., and Kristine Peterson, are nominated for three-year terms expiring in 2028.

• Stockholders are asked to ratify PricewaterhouseCoopers LLP as the independent auditor for 2025.

• The board recommends voting FOR both proposals.

• Voting can be done online, by phone, mail, or during the virtual meeting.

• Shareholder proposals for the 2026 meeting must be submitted 90–120 days before the anniversary of the 2025 meeting.

Board of directors and corporate governance

• The board is divided into three classes, with staggered three-year terms; after the 2025 meeting, the board will have seven members.

• Kristine Peterson serves as Lead Independent Director; the board includes a majority of independent directors.

• Committees include audit, compensation, and nominating/governance, each with independent members and defined charters.

• The board encourages, but does not require, directors to attend the annual meeting.

• No director attended fewer than 75% of meetings in 2024.